BioCentury | Feb 9, 2018
Company News

Lee's announces several updates

...in China, including Hong Kong and Macau, and Taiwan to hypertension drug aliskiren. Manufacturing of aliskiren...
...treat hypertension. Aliskiren, a renin inhibitor, is marketed as Tekturna in the U.S. and as Rasilez...
...Incline Village, Nev. Lee's Pharmaceutical Holdings Ltd. (HKSE:950), Hong Kong, China Business: Cardiovascular, Cancer, Neurology Chris Lieu aliskiren Rasilez Tekturna Zingo ZKAB001 Lee's...
BioCentury | Jun 29, 2017
Strategy

Lilly goes with the flow

...the Novartis-MIT group built an end-to-end process for the pharma’s high blood pressure drug Rasilez aliskiren...
BioCentury | May 30, 2016
Company News

Novartis, PDL BioPharma deal

...Novartis granted newly launched PDL subsidiary, Noden Pharma DAC, exclusive, worldwide commercialization rights to aliskiren to...
...an aliskiren generic. Aliskiren, a renin inhibitor, is marketed as Tekturna in the U.S. and Rasilez...
BioCentury | Feb 19, 2015
Targets & Mechanisms

Ace of hearts

...don't translate well." While Novartis' approach with LCZ696 - and its other compounds serelaxin and aliskiren...
...for heart failure. The compound is partnered with Endo International plc and GlaxoSmithKline plc . Aliskiren...
...for treatment of hypertension in the U.S. as Tekturna , and in the EU as Rasilez...
BioCentury | Feb 13, 2015
Targets & Mechanisms

Ace of hearts

...don’t translate well.” While Novartis’ approach with LCZ696 - and its other compounds serelaxin and aliskiren...
...for heart failure. The compound is partnered with Endo International plc and GlaxoSmithKline plc . Aliskiren...
...for treatment of hypertension in the U.S. as Tekturna , and in the EU as Rasilez...
BioCentury | Sep 8, 2014
Product Development

Betting big on hearts

...who need more intensive therapy. Novartis markets aliskiren as Tekturna in the U.S. and as Rasilez...
...price of $3,000 per year ($250 per month). The bigger picture Along with serelaxin and aliskiren...
...chronic heart failure. The Phase III ATMOSPHERE study is testing aliskiren monotherapy, enalapril therapy, and aliskiren...
BioCentury | Jun 9, 2014
Clinical News

Renin-angiotensin system regulatory update

...April, PRAC supported the conclusions of an EMA review, which concluded in February 2012 that aliskiren...
...hypertension drug Rasilez / Tekturna aliskiren from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) and other aliskiren-containing...
BioCentury | Sep 9, 2013
Clinical News

Aliskiren: Phase III data

...evaluable patients in the double-blind, international Phase III AQUARIUS trial showed that once-daily 300 mg aliskiren...
...vs. placebo. Specifically, aliskiren reduced PAV by 0.33% vs. a 0.11% increase for placebo (p=0.08). Aliskiren...
...hypertension. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Aliskiren ( Rasilez , Tekturna ) ( SPP100...
BioCentury | Jul 15, 2013
Clinical News

Aprovel irbesartan regulatory update

...diabetes or moderate to severe renal impairment (glomerular filtration rate <60 mL/min/1.73 m2) who take aliskiren-containing...
...hypertension drug Rasilez / Tekturna aliskiren from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) and other aliskiren-containing...
...ACE) inhibitors or angiotensin-receptor blockers (ARB). In April 2012, Novartis updated the label for Tekturna aliskiren...
BioCentury | Jul 15, 2013
Clinical News

CoAprovel irbesartan/hydrochlorothiazide regulatory update

...diabetes or moderate to severe renal impairment (glomerular filtration rate <60 mL/min/1.73 m2) who take aliskiren-containing...
...hypertension drug Rasilez / Tekturna aliskiren from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) and other aliskiren-containing...
...ACE) inhibitors or angiotensin-receptor blockers (ARB). In April 2012, Novartis updated the label for Tekturna aliskiren...
Items per page:
1 - 10 of 185